Cartesian Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $78 | $947 | $452 | $298 |
Gross Profit | 78 | 947 | -12,345 | 298 |
EBITDA | -26,499 | -21,939 | -35,296 | 16,475 |
EBIT | -35,902 | 15,886 | ||
Net Income | -39,182 | -92,576 | -35,902 | 15,886 |
Net Change In Cash | 78 | 947 | 452 | 298 |
Free Cash Flow | -22,162 | -18,204 | -16,892 | -20,116 |
Cash | 118,641 | 125,139 | 143,384 | 160,324 |
Basic Shares | 26,855 | 25,973 | 26,002 | 26,447 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,797 | $38,913 | $26,004 | $110,777 |
Gross Profit | 2,797 | 38,913 | 26,004 | 108,740 |
EBITDA | -86,705 | -75,986 | -235,034 | 39,838 |
EBIT | -77,137 | -235,877 | 37,801 | |
Net Income | -130,302 | -77,424 | -219,710 | 35,379 |
Net Change In Cash | 2,797 | 38,913 | 26,004 | 110,777 |
Cost of Revenue | -7,418 | |||
Free Cash Flow | -79,395 | -32,767 | -51,367 | -32,832 |
Cash | 125,139 | 212,610 | 76,911 | 106,438 |
Basic Shares | 25,973 | 23,689 | 5,170 | 4,052 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.94 |
2025-12-31 | -$2.70 |
2025-09-30 | -$1.38 |
2025-06-30 | -$0.77 |